This confirmation would open the possibility of using PSGL-1 as a biomarker of idiopathic PAH and SSc-associated PAH, which would be of great interest given the high PAH prevalence in SSc patients. The gene discussed is SELPLG; the disease is pulmonary arterial hypertension.